Multicentre EECP CHF (congestive heart failure) trial gains FDA go-ahead:
This article was originally published in Clinica
Executive Summary
Vasomedical has received US FDA approval, with conditions, to perform a multicentre, controlled study of its enhanced external counterpulsation (EECP) therapy in congestive heart failure patients. The 18-centre study will assess EECP therapy, which involves wrapping pressurised cuffs around a patient's legs, in 180 subjects. The Westbury, New York company also said that the FDA has classified the EECP system as a Class III PMA device when used in the treatment of CHF.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.